[ad_1]
- CLINICAL BRIEFINGS
Leukaemias characterized by the rearrangement of the gene KMT2A or mutation of the NPM1 gene depend on the protein menin. In a first-in-human trial, the menin inhibitor revumenib had minimal severe adverse effects and showed promising clinical activity in individuals with these types of leukaemia.
[ad_2]
Source link